tosufloxacin and Enterocolitis studies

tosufloxacin: quinolone anti-infective agent; structure given in first source
tosufloxacin : A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin.
7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively.

Enterocolitis: Inflammation of the MUCOSA of both the SMALL INTESTINE and the LARGE INTESTINE. Etiology includes ISCHEMIA, infections, allergic, and immune responses.

Research Excerpts

Excerpt	Relevance	Reference
"Symptomatic nontyphoid salmonella enterocolitis patients were treated with tosufloxacin (TFLX) at oral doses of 150 mg three times a day for 5 to 7 days, but bacterial relapse without symptoms occurred in 85% of the patients within 15 days after the cessation of therapy."	7.71	Salmonella excretion after cessation of tosufloxacin therapy in acute nontyphoid salmonella enterocolitis. ( Kimura, K; Ohnishi, K, 2001)
"Symptomatic nontyphoid salmonella enterocolitis patients were treated with tosufloxacin (TFLX) at oral doses of 150 mg three times a day for 5 to 7 days, but bacterial relapse without symptoms occurred in 85% of the patients within 15 days after the cessation of therapy."	3.71	Salmonella excretion after cessation of tosufloxacin therapy in acute nontyphoid salmonella enterocolitis. ( Kimura, K; Ohnishi, K, 2001)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

tosufloxacin and Enterocolitis

Research Excerpts

Research

Studies (1)

Authors

Other Studies